Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 700

1.

European Academy of Cancer Sciences - position paper.

Adami HO, Berns A, Celis JE, de Vries E, Eggermont A, Harris A, Zur Hausen H, Pelicci PG, Ringborg U.

Mol Oncol. 2018 Sep 21. doi: 10.1002/1878-0261.12379. [Epub ahead of print]

2.

Cancer Core Europe: A European cancer research alliance realizing a research infrastructure with critical mass and programmatic approach to cure cancer in the 21st century.

Calvo F, Apolone G, Baumann M, Caldas C, Celis JE, de Lorenzo F, Ernberg I, Ringborg U, Rowell J, Tabernero J, Voest E, Eggermont A.

Eur J Cancer. 2018 Sep 18;103:155-159. doi: 10.1016/j.ejca.2018.08.023. [Epub ahead of print]

PMID:
30241002
3.

Combination Immunotherapy Development in Melanoma.

Eggermont AMM, Crittenden M, Wargo J.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):197-207. doi: 10.1200/EDBK_201131.

4.

A roadmap for restoring trust in Big Data.

Lawler M, Morris AD, Sullivan R, Birney E, Middleton A, Makaroff L, Knoppers BM, Horgan D, Eggermont A.

Lancet Oncol. 2018 Aug;19(8):1014-1015. doi: 10.1016/S1470-2045(18)30425-X. No abstract available.

PMID:
30102210
5.

Adjuvant Pembrolizumab in Resected Stage III Melanoma.

Eggermont AMM, Robert C, Suciu S.

N Engl J Med. 2018 Aug 9;379(6):593-595. doi: 10.1056/NEJMc1807505. No abstract available.

6.

Reply to 'Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma'.

Jacquelot N, Zitvogel L, Eggermont AM.

Nat Commun. 2018 Jul 26;9(1):2922. doi: 10.1038/s41467-018-05048-0. No abstract available.

7.

Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC18961 trial.

Michels J, Becker N, Suciu S, Kaiser I, Benner A, Kosaloglu-Yalcin Z, Agoussi S, Halama N, Pawlita M, Waterboer T, Eichmüller SB, Jäger D, Eggermont AMM, Zörnig I.

Oncoimmunology. 2018 Feb 12;7(6):e1428157. doi: 10.1080/2162402X.2018.1428157. eCollection 2018.

8.

The new era of adjuvant therapies for melanoma.

Eggermont AMM, Robert C, Ribas A.

Nat Rev Clin Oncol. 2018 Sep;15(9):535-536. doi: 10.1038/s41571-018-0048-5. No abstract available.

9.

Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations.

Verver D, van Klaveren D, van Akkooi ACJ, Rutkowski P, Powell BWEM, Robert C, Testori A, van Leeuwen BL, van der Veldt AAM, Keilholz U, Eggermont AMM, Verhoef C, Grünhagen DJ.

Eur J Cancer. 2018 Jun;96:25-33. doi: 10.1016/j.ejca.2018.02.022. Epub 2018 Apr 13.

PMID:
29660597
10.

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi ACJ, Suciu S, Robert C.

N Engl J Med. 2018 May 10;378(19):1789-1801. doi: 10.1056/NEJMoa1802357. Epub 2018 Apr 15.

PMID:
29658430
11.

European Academy of Cancer Sciences-Designation of Comprehensive Cancer Centres of Excellence.

Ringborg U, Celis J, Eggermont A, Berns A.

Eur J Cancer. 2018 Apr;93:138-139. doi: 10.1016/j.ejca.2018.01.003. Epub 2018 Feb 14. No abstract available.

PMID:
29454744
12.

Lymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studies.

Testori AA, Suciu S, van Akkooi ACJ, Suppa M, Eggermont AMM, de Vries E, Joosse A; European Organization for Research and Treatment of Cancer (EORTC) Melanoma Group.

Melanoma Res. 2018 Jun;28(3):222-229. doi: 10.1097/CMR.0000000000000433.

PMID:
29432281
13.

Neoadjuvant therapy in melanoma: the next step?

Ascierto PA, Eggermont AMM.

Lancet Oncol. 2018 Feb;19(2):151-153. doi: 10.1016/S1470-2045(18)30016-0. Epub 2018 Jan 18. No abstract available.

PMID:
29361473
14.

Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3.

Buart S, Terry S, Noman MZ, Lanoy E, Boutros C, Fogel P, Dessen P, Meurice G, Gaston-Mathé Y, Vielh P, Roy S, Routier E, Marty V, Ferlicot S, Legrès L, Bouchtaoui ME, Kamsu-Kom N, Muret J, Deutsch E, Eggermont A, Soria JC, Robert C, Chouaib S.

Oncotarget. 2017 Oct 30;8(65):108786-108801. doi: 10.18632/oncotarget.22150. eCollection 2017 Dec 12.

15.

Development and evaluation of an isolated limb infusion model for investigation of drug delivery kinetics to solid tumors by thermosensitive liposomes and hyperthermia.

Lokerse WJM, Eggermont AMM, Grüll H, Koning GA.

J Control Release. 2018 Jan 28;270:282-289. doi: 10.1016/j.jconrel.2017.12.012. Epub 2017 Dec 18.

PMID:
29269141
16.

Pre-SN Ultrasound-FNAC can be Sensitive for Lymph Node Metastases in Melanoma Patients if Performed with the Use of the Berlin Criteria.

Voit CA, van Akkooi ACJ, Catalano O, Eggermont AMM.

Ann Surg Oncol. 2017 Dec;24(Suppl 3):661-662. doi: 10.1245/s10434-017-6230-7. Epub 2017 Nov 20. No abstract available.

PMID:
29159735
17.

The need for a network to establish and validate predictive biomarkers in cancer immunotherapy.

Masucci GV, Cesano A, Eggermont A, Fox BA, Wang E, Marincola FM, Ciliberto G, Dobbin K, Puzanov I, Taube J, Wargo J, Butterfield LH, Villabona L, Thurin M, Postow MA, Sondel PM, Demaria S, Agarwala S, Ascierto PA.

J Transl Med. 2017 Nov 3;15(1):223. doi: 10.1186/s12967-017-1325-2.

18.

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L.

Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2.

PMID:
29097494
19.

Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF; for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform.

CA Cancer J Clin. 2017 Nov;67(6):472-492. doi: 10.3322/caac.21409. Epub 2017 Oct 13.

20.

The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.

Eggermont AMM, Dummer R.

Eur J Cancer. 2017 Nov;86:101-105. doi: 10.1016/j.ejca.2017.09.014. Epub 2017 Sep 29.

PMID:
28968566
21.

Predictors of responses to immune checkpoint blockade in advanced melanoma.

Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L.

Nat Commun. 2017 Sep 19;8(1):592. doi: 10.1038/s41467-017-00608-2.

22.

Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy.

Suciu S, Eggermont AMM, Lorigan P, Kirkwood JM, Markovic SN, Garbe C, Cameron D, Kotapati S, Chen TT, Wheatley K, Ives N, de Schaetzen G, Efendi A, Buyse M.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx133. Review.

PMID:
28922786
23.

Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.

Jacquelot N, Pitt JM, Enot DP, Roberti MP, Duong CPM, Rusakiewicz S, Eggermont AM, Zitvogel L.

Oncoimmunology. 2017 Mar 7;6(8):e1299303. doi: 10.1080/2162402X.2017.1299303. eCollection 2017. Review.

24.

Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers.

Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, Casali PG, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, Rauh S, Zielinski CC, Stahel RA, Voest E, Douillard JY, McGregor K, Ciardiello F.

ESMO Open. 2017 Jan 16;1(6):e000142. doi: 10.1136/esmoopen-2016-000142. eCollection 2016. Review.

25.

Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis.

Ives NJ, Suciu S, Eggermont AMM, Kirkwood J, Lorigan P, Markovic SN, Garbe C, Wheatley K; International Melanoma Meta-Analysis Collaborative Group (IMMCG).

Eur J Cancer. 2017 Sep;82:171-183. doi: 10.1016/j.ejca.2017.06.006. Epub 2017 Jul 7. Review.

PMID:
28692949
26.

Corrigendum to "Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy" [Eur J Cancer 67 (2016) 38-45].

Tromme I, Legrand C, Devleesschauwer B, Leiter U, Suciu S, Eggermont A, Sacré L, Baurain JF, Thomas L, Beutels P, Speybroeck N.

Eur J Cancer. 2017 Sep;82:247. doi: 10.1016/j.ejca.2017.06.001. Epub 2017 Jun 26. No abstract available.

PMID:
28662904
27.

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.

Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, Seliger B, Marincola FM.

Eur J Cancer. 2017 Aug;81:116-129. doi: 10.1016/j.ejca.2017.01.035. Epub 2017 Jun 15. Review.

PMID:
28623775
28.

Germline CDKN2A/P16INK4A mutations contribute to genetic determinism of sarcoma.

Jouenne F, Chauvot de Beauchene I, Bollaert E, Avril MF, Caron O, Ingster O, Lecesne A, Benusiglio P, Terrier P, Caumette V, Pissaloux D, de la Fouchardière A, Cabaret O, N'Diaye B, Velghe A, Bougeard G, Mann GJ, Koscielny S, Barrett JH, Harland M, Newton-Bishop J, Gruis N, Van Doorn R, Gauthier-Villars M, Pierron G, Stoppa-Lyonnet D, Coupier I, Guimbaud R, Delnatte C, Scoazec JY, Eggermont AM, Feunteun J, Tchertanov L, Demoulin JB, Frebourg T, Bressac-de Paillerets B.

J Med Genet. 2017 Sep;54(9):607-612. doi: 10.1136/jmedgenet-2016-104402. Epub 2017 Jun 7.

29.

Comparing the therapeutic potential of thermosensitive liposomes and hyperthermia in two distinct subtypes of breast cancer.

Lokerse WJM, Bolkestein M, Dalm SU, Eggermont AMM, de Jong M, Grüll H, Koning GA.

J Control Release. 2017 Jul 28;258:34-42. doi: 10.1016/j.jconrel.2017.05.005. Epub 2017 May 4.

PMID:
28479096
30.

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.

Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, Vaysse T, Marthey L, Eggermont A, Asvatourian V, Lanoy E, Mateus C, Robert C, Carbonnel F.

Ann Oncol. 2017 Jun 1;28(6):1368-1379. doi: 10.1093/annonc/mdx108.

PMID:
28368458
31.

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.

Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, Hollebecque A, Verlingue L, Ileana E, Rosellini S, Ammari S, Ngo-Camus M, Bahleda R, Gazzah A, Varga A, Postel-Vinay S, Loriot Y, Even C, Breuskin I, Auger N, Job B, De Baere T, Deschamps F, Vielh P, Scoazec JY, Lazar V, Richon C, Ribrag V, Deutsch E, Angevin E, Vassal G, Eggermont A, André F, Soria JC.

Cancer Discov. 2017 Jun;7(6):586-595. doi: 10.1158/2159-8290.CD-16-1396. Epub 2017 Apr 1.

32.

Long-term results of ultrasound guided fine needle aspiration cytology in conjunction with sentinel node biopsy support step-wise approach in melanoma.

Oude Ophuis CMC, Verhoef C, Grünhagen DJ, Siegel P, Schoengen A, Röwert-Huber J, Eggermont AMM, Voit CA, van Akkooi ACJ.

Eur J Surg Oncol. 2017 Aug;43(8):1509-1516. doi: 10.1016/j.ejso.2017.02.009. Epub 2017 Feb 21.

PMID:
28262276
33.

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).

Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M.

ESMO Open. 2016 Dec 7;1(6):e000107. doi: 10.1136/esmoopen-2016-000107. eCollection 2016. Review.

34.

Timing of completion lymphadenectomy after positive sentinel node biopsy in patients with melanoma.

Oude Ophuis CM, van Akkooi AC, Rutkowski P, Powell WE, Robert C, Testori A, van Leeuwen BL, Siegel P, Eggermont AM, Verhoef C, Grünhagen DJ.

Br J Surg. 2017 May;104(6):726-733. doi: 10.1002/bjs.10475. Epub 2017 Feb 20.

PMID:
28218385
35.

Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer.

Fend L, Rusakiewicz S, Adam J, Bastien B, Caignard A, Messaoudene M, Iribarren C, Cremer I, Marabelle A, Borg C, Semeraro M, Barraud L, Limacher JM, Eggermont A, Kroemer G, Zitvogel L.

Oncoimmunology. 2016 May 13;6(1):e1163456. doi: 10.1080/2162402X.2016.1163456. eCollection 2017.

36.

NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.

Rusakiewicz S, Perier A, Semeraro M, Pitt JM, Pogge von Strandmann E, Reiners KS, Aspeslagh S, Pipéroglou C, Vély F, Ivagnes A, Jegou S, Halama N, Chaigneau L, Validire P, Christidis C, Perniceni T, Landi B, Berger A, Isambert N, Domont J, Bonvalot S, Terrier P, Adam J, Coindre JM, Emile JF, Poirier-Colame V, Chaba K, Rocha B, Caignard A, Toubert A, Enot D, Koch J, Marabelle A, Lambert M, Caillat-Zucman S, Leyvraz S, Auclair C, Vivier E, Eggermont A, Borg C, Blay JY, Le Cesne A, Mir O, Zitvogel L.

Oncoimmunology. 2016 Apr 25;6(1):e1137418. doi: 10.1080/2162402X.2015.1137418. eCollection 2017.

37.

Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.

Coens C, Suciu S, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Bottomley A, Kotapati S, de Pril V, Testori A, Eggermont AM.

Lancet Oncol. 2017 Mar;18(3):393-403. doi: 10.1016/S1470-2045(17)30015-3. Epub 2017 Feb 3.

38.

Ipilimumab Adjuvant Therapy in Melanoma.

Eggermont AMM, Suciu S, Testori A.

N Engl J Med. 2017 Jan 26;376(4):399. doi: 10.1056/NEJMc1615564. No abstract available.

39.

Melanomas prevent endothelial cell death under restrictive culture conditions by signaling through AKT and p38 MAPK/ ERK-1/2 cascades.

Das AM, Pescatori M, Vermeulen CE, Rens JA, Seynhaeve AL, Koning GA, Eggermont AM, Ten Hagen TL.

Oncoimmunology. 2016 Aug 12;5(10):e1219826. eCollection 2016.

40.

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2016 Nov 15;14(1):313.

41.

A systematic review examining factors influencing health related quality of life among melanoma cancer survivors.

Hamel JF, Pe M, Coens C, Martinelli F, Eggermont AM, Brandberg Y, Bottomley A.

Eur J Cancer. 2016 Dec;69:189-198. doi: 10.1016/j.ejca.2016.10.008. Epub 2016 Nov 11. Review.

PMID:
27838512
42.

A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents.

Azan A, Caspers PJ, Bakker Schut TC, Roy S, Boutros C, Mateus C, Routier E, Besse B, Planchard D, Seck A, Kamsu Kom N, Tomasic G, Koljenović S, Noordhoek Hegt V, Texier M, Lanoy E, Eggermont AM, Paci A, Robert C, Puppels GJ, Mir LM.

Cancer Res. 2017 Jan 15;77(2):557-565. doi: 10.1158/0008-5472.CAN-16-1733. Epub 2016 Nov 11.

43.

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, Chaput N, Eggermont A, Marabelle A, Soria JC, Ferté C.

Clin Cancer Res. 2017 Apr 15;23(8):1920-1928. doi: 10.1158/1078-0432.CCR-16-1741. Epub 2016 Nov 8.

44.

Adjuvant ipilimumab in stage III melanoma: New landscape, new questions.

Eggermont AM.

Eur J Cancer. 2016 Dec;69:39-42. doi: 10.1016/j.ejca.2016.10.009. Epub 2016 Nov 4.

PMID:
27816830
45.

Trial Watch: Immunotherapy plus radiation therapy for oncological indications.

Vacchelli E, Bloy N, Aranda F, Buqué A, Cremer I, Demaria S, Eggermont A, Formenti SC, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2016 Jul 25;5(9):e1214790. eCollection 2016. Review.

46.

Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects.

Daillère R, Vétizou M, Waldschmitt N, Yamazaki T, Isnard C, Poirier-Colame V, Duong CPM, Flament C, Lepage P, Roberti MP, Routy B, Jacquelot N, Apetoh L, Becharef S, Rusakiewicz S, Langella P, Sokol H, Kroemer G, Enot D, Roux A, Eggermont A, Tartour E, Johannes L, Woerther PL, Chachaty E, Soria JC, Golden E, Formenti S, Plebanski M, Madondo M, Rosenstiel P, Raoult D, Cattoir V, Boneca IG, Chamaillard M, Zitvogel L.

Immunity. 2016 Oct 18;45(4):931-943. doi: 10.1016/j.immuni.2016.09.009. Epub 2016 Oct 4.

47.

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.

Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Bastholt L, Mortier L, Thomas L, Tahir S, Hauschild A, Hassel JC, Hodi FS, Taitt C, de Pril V, de Schaetzen G, Suciu S, Testori A.

N Engl J Med. 2016 Nov 10;375(19):1845-1855. Epub 2016 Oct 7.

48.

Effects of time interval between primary melanoma excision and sentinel node biopsy on positivity rate and survival.

Oude Ophuis CM, van Akkooi AC, Rutkowski P, Voit CA, Stepniak J, Erler NS, Eggermont AM, Wouters MW, Grünhagen DJ, Verhoef CK.

Eur J Cancer. 2016 Nov;67:164-173. doi: 10.1016/j.ejca.2016.08.014. Epub 2016 Sep 24.

PMID:
27669503
49.

Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy.

Tromme I, Legrand C, Devleesschauwer B, Leiter U, Suciu S, Eggermont A, Sacré L, Baurain JF, Thomas L, Beutels P, Speybroeck N.

Eur J Cancer. 2016 Nov;67:38-45. doi: 10.1016/j.ejca.2016.07.020. Epub 2016 Sep 2. Erratum in: Eur J Cancer. 2017 Sep;82:247.

PMID:
27592070
50.

Tissue inhibitor of metalloproteinase-3 (TIMP3) expression decreases during melanoma progression and inhibits melanoma cell migration.

Das AM, Bolkestein M, van der Klok T, Oude Ophuis CM, Vermeulen CE, Rens JA, Dinjens WN, Atmodimedjo PN, Verhoef C, Koljenović S, Smits R, Ten Hagen TL, Eggermont AM.

Eur J Cancer. 2016 Oct;66:34-46. doi: 10.1016/j.ejca.2016.06.020. Epub 2016 Aug 11.

PMID:
27522248

Supplemental Content

Loading ...
Support Center